Related Experiment Videos
[Thalidomide. Clinical trials in cancer]
1II Cátedra de Farmacología, Facultad de Medicina, Universidad de Buenos Aires. politi@ciudad.com.ar
Medicina
|February 24, 2001
Summary
Thalidomide exhibits anti-angiogenic properties, showing antitumor activity in certain cancers like Kaposi sarcoma and multiple myeloma. Further randomized trials are needed to confirm its role in treating human neoplasia.
Area of Science:
- Oncology
- Pharmacology
Context:
- Thalidomide's anti-angiogenic effects have spurred clinical trials for various cancers.
- The drug inhibits key angiogenic factors such as bFGF, VEGF, and interleukin-6, and down-regulates TNF-alpha.
Purpose:
- To evaluate the clinical efficacy and safety of thalidomide in treating solid tumors and hematologic malignancies.
- To assess thalidomide's activity across different cancer types, including AIDS-related Kaposi sarcoma, glioma, multiple myeloma, and prostate cancer.
Summary:
- Thalidomide demonstrated clinical antitumor activity as a single agent in phase II trials for specific cancers, including refractory multiple myeloma and hormone-refractory prostate cancer.
- However, thalidomide was found inactive in breast, lung, and kidney cancers.
- The primary dose-limiting toxicity is sedation, with other adverse effects including rash, constipation, and peripheral neuropathy. Its teratogenic potential is a significant concern.
Impact:
- Thalidomide offers advantages such as oral administration, a milder toxicity profile compared to chemotherapy, and low cost.
- Randomized clinical trials are essential to definitively establish thalidomide's therapeutic role in human neoplasia.